Amplifica is a clinical-stage biopharmaceutical company focused on developing injectable therapies aimed at reactivating dormant hair follicles and promoting new hair growth. The company has built a proprietary portfolio of signaling molecules that regulate the hair follicle growth cycle and said its candidates activate follicle regeneration through distinct, complementary mechanisms of action. Amplifica will be initiating product development programs and clinical trials to evaluate safety and efficacy and to seek regulatory approvals. The company’s currently marketed products are primarily intended to slow or prevent further hair loss, while the pipeline targets regeneration. Amplifica raised $26 million in an oversubscribed Series B Preferred Stock financing to fund its clinical development plans. The company is based in San Diego and is addressing androgenetic alopecia, a condition the company notes affects over 50 million men and over 30 million women in the United States.

Total raised

$38M

Funding rounds

5

Latest round

Series B

Latest activity

Aug 2026